Pharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company's commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. The Company markets IMBRUVICA in the United States for four United States. Food and Drug Administration (FDA) approved indications for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17 (del 17p CLL); mantle cell lymphoma (MCL) who have received at least one prior therapy, and all lines of Waldenstrom's macroglobulinemia (WM). It is also pursuing the development of IMBRUVICA for Graft versus host disease (GvHD). In addition, it has a pre-clinical testing program underway to develop inhibitors of BTK for inflammatory and autoimmune diseases.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:PCYC
- CUSIP: 71693310
- Web: N/A
- 50 Day Moving Avg: $256.91
- 200 Day Moving Avg: $195.29
- 52 Week Range: $85.50 - $261.68
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 48.97
- P/E Growth: 0.00
- Average Volume: 1.33 million shs.
Frequently Asked Questions for Pharmacyclics (NASDAQ:PCYC)
What is Pharmacyclics' stock symbol?
Pharmacyclics trades on the NASDAQ under the ticker symbol "PCYC."
How were Pharmacyclics' earnings last quarter?
Pharmacyclics, Inc. (NASDAQ:PCYC) released its earnings results on Friday, May, 1st. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.11 by $0.02. The firm earned $206 million during the quarter, compared to the consensus estimate of $226.27 million. View Pharmacyclics' Earnings History.
Who are some of Pharmacyclics' key competitors?
Some companies that are related to Pharmacyclics include Amgen (AMGN), Celgene (CELG), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Grifols SA, Barcelona (GRFS), Incyte (INCY), Illumina (ILMN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Seattle Genetics (SGEN), Jazz Pharmaceuticals plc - (JAZZ), TESARO (TSRO), Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), BIO-TECHNE Corp (TECH) and Kite Pharma (KITE).
How do I buy Pharmacyclics stock?
Shares of Pharmacyclics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Pharmacyclics stock cost?
One share of Pharmacyclics stock can currently be purchased for approximately $257.10.
Consensus Ratings for Pharmacyclics (NASDAQ:PCYC) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Pharmacyclics (NASDAQ:PCYC)
(Data available from 5/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|5/29/2015||BTIG Research||Reiterated Rating||Neutral||N/A|
Earnings History for Pharmacyclics (NASDAQ:PCYC)Earnings History by Quarter for Pharmacyclics (NASDAQ:PCYC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/1/2015||Q115||$0.11||$0.13||$226.27 million||$206.00 million||View||N/A|
|2/18/2015||Q414||$0.76||$0.96||$267.50 million||$290.00 million||View||N/A|
|11/4/2014||Q314||$0.37||$0.69||$201.50 million||$207.10 million||View||N/A|
|7/31/2014||Q214||($0.23)||($0.26)||$95.88 million||$113.00 million||View||N/A|
|5/2/2014||Q114||$0.17||$0.40||$105.38 million||$119.40 million||View||N/A|
|2/20/2014||Q413||$0.67||$0.95||$85.69 million||$123.60 million||View||N/A|
|7/31/2013||Q2 2013||($0.07)||$0.26||$52.00 million||$54.70 million||View||N/A|
|5/1/2013||Q3 2013||($0.03)||($0.40)||$2.84 million||View||N/A|
|2/14/2013||Q2 2013||$0.29||$0.62||$45.74 million||$57.96 million||View||N/A|
|11/5/2012||Q113||$0.75||$1.14||$87.64 million||$102.70 million||View||N/A|
|9/5/2012||Q412||($0.27)||($0.22)||$3.49 million||$2.10 million||View||N/A|
Earnings Estimates for Pharmacyclics (NASDAQ:PCYC)
Current Year EPS Consensus Estimate: $0.73 EPS
Next Year EPS Consensus Estimate: $5.25 EPS
Dividend History for Pharmacyclics (NASDAQ:PCYC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Pharmacyclics (NASDAQ:PCYC)Insider Trades by Quarter for Pharmacyclics (NASDAQ:PCYC)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/13/2015||Manmeet Singh Soni||CFO||Sell||27,514||$254.24||$6,995,159.36|| |
|3/12/2015||Heow Tan||Insider||Sell||1,000||$254.51||$254,510.00|| |
|11/12/2014||Maky Zanganeh||COO||Sell||30,482||$134.69||$4,105,620.58|| |
|11/10/2014||Maky Zanganeh||COO||Sell||23,000||$133.83||$3,078,090.00|| |
|11/10/2014||Richard B Love||General Counsel||Sell||1,500||$133.87||$200,805.00|| |
|11/7/2014||Maky Zanganeh||COO||Sell||1,551||$135.01||$209,400.51|| |
|11/7/2014||Maria Fardis||Insider||Sell||5,000||$134.50||$672,500.00|| |
|9/4/2014||Maky Zanganeh||COO||Sell||12,000||$121.75||$1,461,000.00|| |
|8/27/2014||Richard B Love||General Counsel||Sell||1,500||$124.00||$186,000.00|| |
|8/13/2014||Heow Tan||Insider||Sell||10,000||$123.58||$1,235,800.00|| |
|8/7/2014||Jesse Mcgreivy||Insider||Sell||34,062||$120.92||$4,118,777.04|| |
|3/5/2014||Boultbee Paula Sjovall||EVP||Sell||20,000||$138.22||$2,764,400.00|| |
|3/5/2014||Gregory Hemmi||VP||Sell||15,000||$140.00||$2,100,000.00|| |
|3/5/2014||Jesse Mcgreivy||Insider||Sell||6,563||$139.66||$916,588.58|| |
|3/4/2014||Betty Chang||VP||Sell||17,500||$137.97||$2,414,475.00|| |
|2/27/2014||Den Broek Richard Van||Director||Sell||78,835||$146.63||$11,559,576.05|| |
|12/19/2013||Heow Tan||Insider||Sell||5,000||$100.87||$504,350.00|| |
|12/18/2013||Gregory Hemmi||VP||Sell||20,000||$100.52||$2,010,400.00|| |
|12/16/2013||Rainer Erdtmann||VP||Sell||54,000||$107.77||$5,819,580.00|| |
|6/6/2013||Scott T Shearer||VP||Sell||18,750||$85.17||$1,596,937.50|| |
|5/31/2013||Heow Tan||Insider||Sell||5,237||$91.84||$480,966.08|| |
|5/31/2013||Jesse Mcgreivy||VP||Sell||14,479||$91.13||$1,319,471.27|| |
|2/5/2013||David J Loury||Insider||Sell||20,000||$70.58||$1,411,600.00|| |
|12/28/2012||Den Broek Richard Van||Director||Sell||30,285||$57.99||$1,756,227.15|| |
|12/27/2012||Gregory Hemmi||VP||Sell||13,000||$59.20||$769,600.00|| |
Headline Trends for Pharmacyclics (NASDAQ:PCYC)
Latest Headlines for Pharmacyclics (NASDAQ:PCYC)
Pharmacyclics (PCYC) Chart for Wednesday, May, 24, 2017